The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients
Oncol Lett
07 June 2022
https://pubmed.ncbi.nlm.nih.gov/35761946/
Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
Curr Oncol Rep
01 June 2022
https://pubmed.ncbi.nlm.nih.gov/35648340/
LDN Webinar Presentation 18 May 2022: Dr Masoud Rashidi - LDN, Dosing, Fillers and Compounded Options. LDN, ULDN and Pain/Opioid Issues
Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/
LDN Webinar Presentation 18 May 2022: Dr Mathewson - LDN as supportive care for Oncology and Autoimmune patients: Case Reviews
Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/
LDN Webinar Presentation 18 May 2022: Dr Sato-Re - How and why I prescribe LDN in my integrative and general practice
Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/
LDN Webinar 18 May 2022 (LDN; low dose naltrexone)
LDN Questions Answered Live by
Pharmacist Dr Masoud Rashidi - LDN Specialist
Dr Sato-Re
Dr Mathewson
Sponsored by Innovative Compounding Pharmacy icpfolsom.com
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
GlobalNewswire
27 April 2022
https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html
Yusuf (JP) Saleeby, MD - LDN to help Long Covid patients; March 2022 (LDN, low dose naltrexone)
Discussing Low-Dose Naltrexone with Sajad Zalzala
Lifespan.io
20 April 2022
https://www.lifespan.io/news/discussing-low-dose-naltrexone-with-sajad-zalzala/
This drug, known for curbing addictions, has shown other benefits in some patients. Dr. Zalzala responds to questions on the use of low dose naltrexone (LDN).